Clinical trial
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With…
NCT00088543 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00088543 |
|---|---|
| Title | Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant |
| Official title | Pilot Trial of Two Dose Levels of Thymoglobulin as Part of a Myeloablative-Conditioning for a Human Leukocyte Antigen (HLA) Identical Matched Related Donor (MRD) Stem Cell Transplant (SCT) With Cyclosporine (CSa) as Post-transplant Graft vs. Host Disease (GvHD) Prophylaxis |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD) |
| Intervention type | Biological |
| Interventions | Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)] |
| Enrollment | 60 |
| Start date | Mar 1, 2004 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Jul 30, 2004 |
| Last update posted | Mar 18, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: